Bioventus Inc. — Earnings Quality Grade F
BVS · Healthcare
Major red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 82 days, change +1 days YoY
AR growth 0.7% vs revenue growth -0.9%
Revenue -0.9%, CFFO 92.5%. Cash follows revenue
Expense Quality
Inventory -11.1% vs COGS -2.8%. Normal
CapEx growth 154.7% is >2x revenue growth -0.9%
SG&A/Gross Profit = 80.9%, exceeds 70%
Gross margin 68.3%, change +0.6pp. Stable
Cash Flow Quality
CFFO/NI = 3.28. Profits backed by cash
FCF $0.1B, FCF/NI = 3.17
Accruals ratio = -7.6%. Low accruals
Cash $0.1B covers only 17% of debt $0.3B
Balance Sheet Health
Goodwill+Intangibles $0.4B = 204% of equity. Over 50%
Debt/EBITDA = 3.0x. Healthy
Other assets grew 21.2% vs revenue -0.9%
No write-off data
Acquisition Risk
FCF after acquisitions positive
Goodwill+Intangibles change -9% YoY. Normal
Manipulation Score
M-Score = -2.80 (< -2.22). Unlikely manipulator
Portfolio monitoring
Monitor BVS continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25